Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-09-27
1995-12-19
Criares, T. J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31495
Patent
active
054768543
ABSTRACT:
Methods and compositions are disclosed utilizing the optically pure (R)-isomer of lomefloxacin. This compound is a potent drug for the treatment of infection or other diseases requiring antibiotics while avoiding the concomitant liability of adverse effects that are associated with the racemic mixture of lomefloxacin.
REFERENCES:
patent: 4528287 (1985-07-01), Itoh et al.
patent: 4992445 (1991-02-01), Lawter et al.
Blum, R. A., "Influence of Renal Function on the Pharmacokinetics of Lomefloxacin Compared With Other Fluoroquinolones", The American Journal of Medicine 92(4A): 18S-21S (1992).
Cox, C. E., "A Comparison of the Safety and Efficacy of Lomefloxacin and Ciprofloxacin in the Treatment of Complicated or Recurrent Urinary Tract Infections", The American Journal of Medicine 92(4A):82S-86S (1992).
Felmingham, D. and Robbins, M. J., "In vitro Activity of Lomefloxacin and Other Antimicrobials Against Bacterial Enteritis Pathogens", Diagn. Microbiol. Infect. Dis. 15: 339-343 (1992).
Iravani, A., "Efficacy of Lomefloxacin as Compared to Norfloxacin in the Treatment of Uncomplicated Urinary Tract Infections in Adults", The American Journal of Medicine 92(4A): 75S-81S (1992).
Lebrec, D., "Pharmacokinetics of Lomefloxacin in Patients with Cirrhosis", The American Journal of Medicine 92(4A): 41S-44S (1992).
Nilsen, O. G., "Single-Dose Pharmacolinetics of Lomefloxacin in Patients with Normal and Impaired Renal Function", The American Journal of Medicine 92(4A): 38S-40S (1992).
Paton, J. and Reeves, D., "Clinical Features and Management of Adverse Effects of Quinolone Antibacterials", Drug Safety 6(1): 8-27 (1991).
Christ, W., "Central Nervous System Toxicity of Quinolones: Human and Animal Findings", Journal of Antimicrobial Chemotherapy 26, Suppl. B.: 219-225 (1990).
Morse, I., "Pharmacokinetics and Safety of Single Oral Doses of Lomefloxacin", Biopharmaceutics & Drug Disposition vol. II: 543-551 (1990).
Neu, H. C., "Use of Fluoroquinolone Antimicrobial Agents by Cardiovascular and Cardiopulmonary Surgeons", Texas Heart Institute Journal 17(1): 12-21 (1990).
Okamoto, Y. et al., "Optical resolution of dihydropyridine enantiomers by High-performance liquid chromatography using phenylcarbamates of polysaccharides as a chiral stationary phase", Journal of Chromatography 513: ???-378 (1990).
Scripp's New Product Report, "Lomefloxacin", PJB Publications Ltd., Nov. 1990.
Soons, P. A. et al., "Enantioselective determination of felodipine and other chiral dihydropyridine calcium entry blockers in human plasma", Journal of Chromatography 528: 343-356 (1990).
Wagai, N. et al., "Phototoxic potential of quinolone antibacterial agents in Balb/c mice", Toxicology Letters 54: 299-308 (1990).
Hunt, T. L. and Adams, M. A., "Pharmacokinetics and Safety of Lomefloxacin Following Multiple Doses", Diagn. Microbiol. Infect. Dis. 12: 181-187 (1989).
Magalhaes, M. et al., "Lomefloxacin Activity Against 2,813 Clinical Isolates: A Collaborative Study at Three Medical Centers in Brazil", 12: 35S-39S (1989).
Simor, A. E. et al., "Comparative In Vitro Activities of Six New Fluorozuinolones and Other Oral Antimicrobial Agents against Campylobacter pylon.TM.", Antimicrobial Agents and Chemotherapy 33(1): 108-109 (1989).
Siporin, C., "The Evolution of Fluorinated Quinolones: Pharmacology, Microbiological Activity, Clinical Uses, and Toxicities", Annu. Rev. Microbiol. 43: 601-27 (1989).
Hardy, D. J. et al., "Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones", Journal of Antimicrobial Chemotherapy 22: 631-636 (1988).
Hupertz, V. et al., "Susceptibility of Campylobacter pylori Isolated from Pediatric and Adult Patients to Seven New Quinolone Antibiotics and Nalidixic Acid", Chemotherapy 34: 341-344 (1988).
Une, T. et al., "In Vitro Activity of DR-3355, an Optically Active Ofloxacin", Antimicrobial Agents and Chemotherapy 32(9): 1336-1340 (1988).
Criares T. J.
Sepracor Inc.
LandOfFree
Methods and compositions for treating bacterial infection using does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating bacterial infection using , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating bacterial infection using will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-992240